The following study has recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on clinicaltrials.gov. For more information or questions about a study, please email firstname.lastname@example.org or call 312-355-5112.
MEK-NF-201: a Phase 2b Trial of the MEK ½ Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity
Sponsor: SpringWorks Therapeutics, Inc.
Principal Investigator: Stefania Maraka, MD
This trial is for English-speaking patients only.